The anesthesiologist and pulmonary arterial hypertension

Seminars in Cardiothoracic and Vascular Anesthesia

Volumn 11, Issue 2, 2007, Pages 93-95

  Tidswell, Mark ^a   Higgins, Thomas L ^a  

^a BAYSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; BONE MORPHOGENETIC PROTEIN RECEPTOR 2; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; ENDOGLIN; ILOPROST; PROSTACYCLIN; SILDENAFIL; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 2; UNIPROST;

ANESTHESIST; ANGIOGENESIS; CARDIOVASCULAR RISK; CELL PROLIFERATION; CONTINUOUS INFUSION; DYSPNEA; ECHOCARDIOGRAPHY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; GENETIC DISORDER; HEART CATHETERIZATION; HEART FUNCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION COMPLICATION; LUNG ARTERY PRESSURE; LUNG EMBOLISM; PULMONARY HYPERTENSION; RISK ASSESSMENT; RISK FACTOR; SCLERODERMA; THROMBOEMBOLISM; VASCULAR DISEASE; VASOCONSTRICTION; VASODILATATION;

EID: 34249790142     PISSN: 10892532     EISSN: None     Source Type: Journal    
DOI: 10.1177/1089253207301353     Document Type: Editorial

References (15)

1. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002 ; 346: 896-903.
2. Olschewski H., Simonneau G., Galie N., et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002 ; 347: 322-329.
3. Simonneau G., Barst RJ, Galie N., et al. Treprostinil Study Group. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002 ; 165: 800-804.
4. Galie N., Ghofrani HA, Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005 ; 353: 2148-2157.
5. Simonneau G., Galie N., Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004 ; 43 (suppl): 5-12.
6. Newman JH, Wheeler L., Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med. 2001 ; 345: 319-324.
7. Thomson JR, Machado RD, Pauciulo MW, et al., Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet. 2000 ; 37: 741-745.
8. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-β receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. J Med Genet. 2000 ; 26: 81-84.
9. Trembath RC, Thomson JR, Machado RD, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med. 2001 ; 345: 325-334.
10. Du L., Sullivan CC, Chu D., et al. Signaling molecules in nonfamilial pulmonary hypertension. N Engl J Med. 2003 ; 348: 500-509.
11. Pengo V., Lensing A., Prins MH, et al. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004 ; 350: 2257-2264.
12. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. 1996 ; 334: 296-301.
13. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002 ; 40: 780-788.
14. Farber HW, Loscalzo J. Pulmonary arterial hypertension. N Engl J Med. 2004 ; 351: 1655-1665.
15. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004 ; 126 (Suppl): 35-62.